BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression
Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to comb...
Saved in:
| Published in | Experimental & molecular medicine Vol. 55; no. 2; pp. 364 - 376 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.02.2023
Springer Nature B.V Nature Publishing Group 생화학분자생물학회 |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma.
Cancer: a drug combination for combating melanoma
Drugs that target proteins involved in issuing stop and start commands to cancer-related genes help to sensitize melanoma cells to a widely used anti-cancer therapy, leading to tumor shrinkage in mice. Furong Zeng from Central South University in Changsha, China, and colleagues screened 240 approved anti-cancer agents in search of molecules that work synergistically with a BET inhibitor, an inhibitor of these proteins, to induce the death of melanoma cells. They found that a protein targeted by BET inhibitors (JQ1 and NHWD-870) regulates a growth factor protein, whose altered expression then helps to sensitize melanoma cells to sunitinib. Sunitinib is approved to treat several types of cancer and works by targeting many different kinds of kinase enzymes. The combination of BET inhibitors and sunitinib showed synergistic antitumor effects in a mouse model of melanoma. |
|---|---|
| AbstractList | Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma. KCI Citation Count: 0 Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma. Cancer: a drug combination for combating melanoma Drugs that target proteins involved in issuing stop and start commands to cancer-related genes help to sensitize melanoma cells to a widely used anti-cancer therapy, leading to tumor shrinkage in mice. Furong Zeng from Central South University in Changsha, China, and colleagues screened 240 approved anti-cancer agents in search of molecules that work synergistically with a BET inhibitor, an inhibitor of these proteins, to induce the death of melanoma cells. They found that a protein targeted by BET inhibitors (JQ1 and NHWD-870) regulates a growth factor protein, whose altered expression then helps to sensitize melanoma cells to sunitinib. Sunitinib is approved to treat several types of cancer and works by targeting many different kinds of kinase enzymes. The combination of BET inhibitors and sunitinib showed synergistic antitumor effects in a mouse model of melanoma. Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma. Cancer: a drug combination for combating melanoma Drugs that target proteins involved in issuing stop and start commands to cancer-related genes help to sensitize melanoma cells to a widely used anti-cancer therapy, leading to tumor shrinkage in mice. Furong Zeng from Central South University in Changsha, China, and colleagues screened 240 approved anti-cancer agents in search of molecules that work synergistically with a BET inhibitor, an inhibitor of these proteins, to induce the death of melanoma cells. They found that a protein targeted by BET inhibitors (JQ1 and NHWD-870) regulates a growth factor protein, whose altered expression then helps to sensitize melanoma cells to sunitinib. Sunitinib is approved to treat several types of cancer and works by targeting many different kinds of kinase enzymes. The combination of BET inhibitors and sunitinib showed synergistic antitumor effects in a mouse model of melanoma. Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma.Cancer: a drug combination for combating melanomaDrugs that target proteins involved in issuing stop and start commands to cancer-related genes help to sensitize melanoma cells to a widely used anti-cancer therapy, leading to tumor shrinkage in mice. Furong Zeng from Central South University in Changsha, China, and colleagues screened 240 approved anti-cancer agents in search of molecules that work synergistically with a BET inhibitor, an inhibitor of these proteins, to induce the death of melanoma cells. They found that a protein targeted by BET inhibitors (JQ1 and NHWD-870) regulates a growth factor protein, whose altered expression then helps to sensitize melanoma cells to sunitinib. Sunitinib is approved to treat several types of cancer and works by targeting many different kinds of kinase enzymes. The combination of BET inhibitors and sunitinib showed synergistic antitumor effects in a mouse model of melanoma. Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma.Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma. Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma. Drugs that target proteins involved in issuing stop and start commands to cancer-related genes help to sensitize melanoma cells to a widely used anti-cancer therapy, leading to tumor shrinkage in mice. Furong Zeng from Central South University in Changsha, China, and colleagues screened 240 approved anti-cancer agents in search of molecules that work synergistically with a BET inhibitor, an inhibitor of these proteins, to induce the death of melanoma cells. They found that a protein targeted by BET inhibitors (JQ1 and NHWD-870) regulates a growth factor protein, whose altered expression then helps to sensitize melanoma cells to sunitinib. Sunitinib is approved to treat several types of cancer and works by targeting many different kinds of kinase enzymes. The combination of BET inhibitors and sunitinib showed synergistic antitumor effects in a mouse model of melanoma. |
| Author | He, Yi Deng, Guangtong Sun, Huiyan Yin, Mingzhu Li, Yayun Meng, Yu Zeng, Furong Chen, Xiang |
| Author_xml | – sequence: 1 givenname: Furong surname: Zeng fullname: Zeng, Furong organization: Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, Department of Oncology, Xiangya Hospital, Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology – sequence: 2 givenname: Yayun surname: Li fullname: Li, Yayun organization: Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology – sequence: 3 givenname: Yu surname: Meng fullname: Meng, Yu organization: Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology – sequence: 4 givenname: Huiyan surname: Sun fullname: Sun, Huiyan organization: Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology – sequence: 5 givenname: Yi surname: He fullname: He, Yi organization: Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology – sequence: 6 givenname: Mingzhu surname: Yin fullname: Yin, Mingzhu email: yinmingzhu2008@126.com organization: Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology – sequence: 7 givenname: Xiang surname: Chen fullname: Chen, Xiang email: chenxiangck@126.com organization: Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology – sequence: 8 givenname: Guangtong surname: Deng fullname: Deng, Guangtong email: dengguangtong@outlook.com organization: Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Clinical Research Center for Cancer Immunotherapy, Xiangya Hospital, Central South University, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36720918$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002937530$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9kktv1DAUhSNURB_wB1igSGwQUsDvOBukUtoyUhESGtaWYzsTTzP2YCeg4ddzmbTQdtGVLd_vHB_de4-LgxCDK4qXGL3DiMr3GRNSiwoRWiHUUFHtnhRHBDWkEgzTgzv3w-I45zVChLOaPSsOqaihhuVR8eXj-bL0ofetH2PKZd4Fl1b-tyt_-bEv8xT86INvgSk3btAhbnQ59ilOq768_HSBOTDbbXI5-xieF087PWT34uY8Kb5fnC_PPldXXy8XZ6dXleE1HytrJRaUm9ayRkqLOeoE49wwiygimFtsjXW24TVFWHSkbShvhCS0Y9LgjtKT4u3sG1Knro1XUfv9uYrqOqnTb8uFwgg3NRcC4MUM26jXapv8RqfdXrF_iGmldBq9GZwSptGWCt6h1jHLrRYYfrUaU-6s0w68Psxe26ndOGtcGJMe7pnerwTfQ6ifqmkkrgUDgzc3Bin-mFwe1cZn4wborItTVqSuoTWCEgno6wfoOk4pQF-BkphhBjMH6tXdRP-i3I4YADkDJsWck-uU8aMeYVoQ0A_QJ_V3m9S8TQq2Se23Se1ASh5Ib90fFdFZlAEOK5f-x35E9QfzNNv2 |
| CitedBy_id | crossref_primary_10_1016_j_ejphar_2024_176382 crossref_primary_10_1080_21541264_2023_2294623 crossref_primary_10_1016_j_bbrc_2023_149209 crossref_primary_10_32604_or_2024_055449 crossref_primary_10_1016_j_ejphar_2024_176894 crossref_primary_10_1038_s41390_023_02729_5 crossref_primary_10_1002_adhm_202402415 crossref_primary_10_1080_14656566_2024_2342403 crossref_primary_10_1038_s41392_023_01647_6 crossref_primary_10_1021_acs_orglett_4c00994 crossref_primary_10_1186_s40779_023_00497_1 crossref_primary_10_1016_j_bcp_2024_116198 crossref_primary_10_1038_s41598_023_38450_w crossref_primary_10_3390_cancers16101794 crossref_primary_10_3390_ijms25137459 crossref_primary_10_1038_s12276_023_01046_5 crossref_primary_10_1002_mco2_684 crossref_primary_10_1016_j_it_2023_10_007 |
| Cites_doi | 10.1038/s41420-021-00462-8 10.15252/emmm.201809081 10.3389/fonc.2019.00268 10.21037/atm-21-4764 10.1056/NEJMra2034861 10.1016/j.cmet.2019.12.005 10.1016/j.jid.2016.07.016 10.1038/s41574-021-00529-7 10.1002/ctm2.722 10.15252/msb.20166796 10.1097/CMR.0000000000000790 10.1158/0008-5472.CAN-08-4323 10.1016/j.ccell.2019.10.002 10.1158/1078-0432.CCR-14-2701 10.1158/1078-0432.CCR-08-1332 10.18632/oncotarget.22696 10.1158/1078-0432.CCR-10-2402 10.1038/s41467-020-15290-0 10.1158/2159-8290.CD-16-1223 10.7150/thno.47432 10.1007/s10565-020-09565-x 10.15252/emmm.201708446 10.1158/1078-0432.CCR-17-3697 10.1080/15548627.2021.1934270 10.1126/scitranslmed.aax2879 10.1158/0008-5472.CAN-18-3177 10.1158/0008-5472.CAN-13-0122-T 10.7150/thno.13178 10.1097/CMR.0000000000000497 10.1126/scitranslmed.aal1645 10.1016/j.jid.2020.12.038 10.1002/cam4.667 10.1161/01.RES.0000202805.73038.48 10.1186/s12935-018-0549-4 10.1158/1078-0432.CCR-07-5212 10.7554/eLife.04640 10.1038/s41416-019-0724-y 10.3390/ijms23031293 10.1158/1078-0432.CCR-11-1987 10.1016/S0140-6736(18)31559-9 10.1056/NEJMoa1604958 10.1016/j.ejca.2022.01.004 10.1158/1078-0432.CCR-12-2731 10.1093/carcin/bgm268 10.1158/2159-8290.CD-17-0401 10.4251/wjgo.v14.i1.75 10.1007/s13258-022-01328-8 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA ACYCR |
| DOI | 10.1038/s12276-023-00936-y |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni) Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 2092-6413 |
| EndPage | 376 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10197566 oai_doaj_org_article_6c9ad365f0be4d5da61823da135edeae PMC9981764 36720918 10_1038_s12276_023_00936_y |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Natural Science Foundation of Hunan Province (Hunan Provincial Natural Science Foundation) grantid: 2021JJ40976 funderid: https://doi.org/10.13039/501100004735 – fundername: China Postdoctoral Science Foundation grantid: 2020M682594, 2021T140748 funderid: https://doi.org/10.13039/501100002858 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 82102803,82272849; 82103183 funderid: https://doi.org/10.13039/501100001809 – fundername: ; grantid: 2021JJ40976 – fundername: ; grantid: 2020M682594, 2021T140748 – fundername: ; grantid: 82102803,82272849; 82103183 |
| GroupedDBID | --- 0R~ 29G 2WC 3V. 5-W 53G 5GY 7X7 87B 88E 8FE 8FH 8FI 8FJ 8JR 9ZL AAJSJ ABUWG ACGFO ACGFS ACPRK ACSMW ACYCR ADBBV AENEX AFKRA AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI C1A C6C CCPQU DIK DU5 E3Z EBLON EBS EF. EJD EMOBN F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE LK8 M1P M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT TR2 UKHRP W2D XSB AASML AAYXX CITATION OVT PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK AARCD AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 PUEGO 5PM AAADF AFGXO |
| ID | FETCH-LOGICAL-c575t-dd81635cbd4988d150f6455c4d030215d1dcded9573016f2b93596823f48c1f33 |
| IEDL.DBID | AAJSJ |
| ISSN | 2092-6413 1226-3613 |
| IngestDate | Thu Mar 07 06:17:14 EST 2024 Wed Aug 27 01:28:13 EDT 2025 Thu Aug 21 18:38:24 EDT 2025 Sun Aug 24 03:50:45 EDT 2025 Wed Aug 13 09:13:47 EDT 2025 Thu Jan 02 22:54:23 EST 2025 Tue Jul 01 04:10:32 EDT 2025 Thu Apr 24 22:54:01 EDT 2025 Fri Feb 21 02:40:06 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c575t-dd81635cbd4988d150f6455c4d030215d1dcded9573016f2b93596823f48c1f33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.nature.com/articles/s12276-023-00936-y |
| PMID | 36720918 |
| PQID | 2781414936 |
| PQPubID | 2041975 |
| PageCount | 13 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10197566 doaj_primary_oai_doaj_org_article_6c9ad365f0be4d5da61823da135edeae pubmedcentral_primary_oai_pubmedcentral_nih_gov_9981764 proquest_miscellaneous_2771636328 proquest_journals_2781414936 pubmed_primary_36720918 crossref_citationtrail_10_1038_s12276_023_00936_y crossref_primary_10_1038_s12276_023_00936_y springer_journals_10_1038_s12276_023_00936_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20230200 2023-02-01 2023-02-00 20230201 2023-02 |
| PublicationDateYYYYMMDD | 2023-02-01 |
| PublicationDate_xml | – month: 2 year: 2023 text: 20230200 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: United States – name: Seoul |
| PublicationTitle | Experimental & molecular medicine |
| PublicationTitleAbbrev | Exp Mol Med |
| PublicationTitleAlternate | Exp Mol Med |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Springer Nature B.V Nature Publishing Group 생화학분자생물학회 |
| Publisher_xml | – name: Nature Publishing Group UK – name: Springer Nature B.V – name: Nature Publishing Group – name: 생화학분자생물학회 |
| References | Zaretsky (CR7) 2016; 375 Zhang (CR33) 2016; 6 Enserink, Chymkowitch (CR24) 2022; 23 Zhao (CR27) 2021; 37 Ambrosini (CR34) 2019; 79 Yin (CR9) 2020; 11 Lee, Jin, Lee, Lee (CR47) 2022; 32 Carson (CR29) 2015; 21 Nakayasu (CR42) 2020; 31 Deng (CR10) 2020; 10 Curti, Faries (CR5) 2021; 384 Kluger (CR40) 2011; 17 Zhou (CR28) 2018; 18 Bai (CR26) 2019; 36 Jiang, Zhou, Giobbie-Hurder, Wargo, Hodi (CR30) 2013; 19 Song (CR4) 2017; 7 Echevarria-Vargas (CR13) 2018; 10 Li (CR20) 2021; 8 Deng (CR2) 2022; 12 Guo, Wang (CR46) 2019; 34 Segura (CR8) 2013; 73 CR44 Luebker, Koepsell (CR3) 2019; 9 Xin (CR48) 2009; 69 Paoluzzi (CR16) 2016; 5 Wang (CR39) 2021; 17 Guo (CR49) 2021; 7 Simpkins (CR23) 2018; 24 Tiago (CR17) 2020; 122 Korkut (CR15) 2015; 4 Minor (CR36) 2012; 18 Kempf (CR43) 2006; 98 Weide (CR41) 2016; 136 Zhao (CR31) 2022; 165 Yang (CR11) 2017; 9 Ko (CR38) 2009; 15 Schadendorf (CR1) 2018; 392 Deng (CR22) 2022; 18 Zhao, Cheng, Zhou (CR18) 2018; 28 Kuang (CR21) 2018; 9 Emran (CR19) 2021; 141 Finke (CR37) 2008; 14 Borlado, Mendez (CR25) 2008; 29 Chen, Yin, Liu (CR45) 2021; 9 Kanojia (CR12) 2020; 12 Shin (CR6) 2017; 7 Sun, Du, Li, Deng, Zeng (CR32) 2022; 14 Fallahi-Sichani (CR14) 2017; 13 Chua (CR35) 2019; 11 D Schadendorf (936_CR1) 2018; 392 D Wang (936_CR39) 2021; 17 T Kempf (936_CR43) 2006; 98 DS Shin (936_CR6) 2017; 7 V Chua (936_CR35) 2019; 11 JH Finke (936_CR37) 2008; 14 AA Emran (936_CR19) 2021; 141 H Li (936_CR20) 2021; 8 Y Zhao (936_CR27) 2021; 37 H Xin (936_CR48) 2009; 69 JM Enserink (936_CR24) 2022; 23 K Zhao (936_CR31) 2022; 165 SA Luebker (936_CR3) 2019; 9 L Paoluzzi (936_CR16) 2016; 5 JM Zaretsky (936_CR7) 2016; 375 C Song (936_CR4) 2017; 7 F Simpkins (936_CR23) 2018; 24 MF Segura (936_CR8) 2013; 73 L Bai (936_CR26) 2019; 36 D Kanojia (936_CR12) 2020; 12 HY Sun (936_CR32) 2022; 14 DR Minor (936_CR36) 2012; 18 G Deng (936_CR2) 2022; 12 LR Borlado (936_CR25) 2008; 29 936_CR44 JS Ko (936_CR38) 2009; 15 J Lee (936_CR47) 2022; 32 G Deng (936_CR10) 2020; 10 G Deng (936_CR22) 2022; 18 M Yin (936_CR9) 2020; 11 A Korkut (936_CR15) 2015; 4 B Weide (936_CR41) 2016; 136 X Kuang (936_CR21) 2018; 9 L Chen (936_CR45) 2021; 9 F Guo (936_CR49) 2021; 7 M Fallahi-Sichani (936_CR14) 2017; 13 M Tiago (936_CR17) 2020; 122 IM Echevarria-Vargas (936_CR13) 2018; 10 HM Kluger (936_CR40) 2011; 17 BD Curti (936_CR5) 2021; 384 X Jiang (936_CR30) 2013; 19 ES Nakayasu (936_CR42) 2020; 31 R Carson (936_CR29) 2015; 21 LL Guo (936_CR46) 2019; 34 Z Zhang (936_CR33) 2016; 6 L Yang (936_CR11) 2017; 9 B Zhao (936_CR18) 2018; 28 G Ambrosini (936_CR34) 2019; 79 C Zhou (936_CR28) 2018; 18 |
| References_xml | – volume: 7 start-page: 78 year: 2021 ident: CR49 article-title: NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15 publication-title: Cell Death Discov. doi: 10.1038/s41420-021-00462-8 – volume: 11 start-page: e9081 year: 2019 ident: CR35 article-title: Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma publication-title: Embo. Mol. Med. doi: 10.15252/emmm.201809081 – volume: 9 start-page: 268 year: 2019 ident: CR3 article-title: Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies publication-title: Front. Oncol. doi: 10.3389/fonc.2019.00268 – volume: 9 start-page: 1547 year: 2021 ident: CR45 article-title: Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K/AKT/FOXO/PPARgamma signaling pathway publication-title: Ann. Transl. Med. doi: 10.21037/atm-21-4764 – volume: 384 start-page: 2229 year: 2021 end-page: 2240 ident: CR5 article-title: Recent advances in the treatment of melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra2034861 – volume: 31 start-page: 363 year: 2020 end-page: 374 e366 ident: CR42 article-title: Comprehensive proteomics analysis of stressed human islets identifies GDF15 as a target for type 1 diabetes intervention publication-title: Cell Metab. doi: 10.1016/j.cmet.2019.12.005 – volume: 136 start-page: 2444 year: 2016 end-page: 2452 ident: CR41 article-title: High GDF-15 serum levels independently correlate with poorer overall survival of patients with tumor-free stage III and unresectable stage IV melanoma publication-title: J. Invest. Dermatol. doi: 10.1016/j.jid.2016.07.016 – volume: 17 start-page: 592 year: 2021 end-page: 607 ident: CR39 article-title: GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease publication-title: Nat. Rev. Endocrinol. doi: 10.1038/s41574-021-00529-7 – volume: 12 year: 2022 ident: CR2 article-title: EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma publication-title: Clin. Transl. Med. doi: 10.1002/ctm2.722 – volume: 13 start-page: 905 year: 2017 ident: CR14 article-title: Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state publication-title: Mol. Syst. Biol. doi: 10.15252/msb.20166796 – volume: 32 start-page: 1 year: 2022 end-page: 10 ident: CR47 article-title: Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization publication-title: Melanoma Res. doi: 10.1097/CMR.0000000000000790 – volume: 69 start-page: 2506 year: 2009 end-page: 2513 ident: CR48 article-title: Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-4323 – volume: 36 start-page: 498 year: 2019 end-page: 511.e417 ident: CR26 article-title: A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.10.002 – volume: 21 start-page: 3230 year: 2015 end-page: 3240 ident: CR29 article-title: HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2701 – volume: 15 start-page: 2148 year: 2009 end-page: 2157 ident: CR38 article-title: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-1332 – volume: 9 start-page: 802 year: 2018 end-page: 811 ident: CR21 article-title: Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma publication-title: Oncotarget doi: 10.18632/oncotarget.22696 – volume: 17 start-page: 2417 year: 2011 end-page: 2425 ident: CR40 article-title: Plasma markers for identifying patients with metastatic melanoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-10-2402 – volume: 11 year: 2020 ident: CR9 article-title: Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction publication-title: Nat. Commun. doi: 10.1038/s41467-020-15290-0 – volume: 7 start-page: 188 year: 2017 end-page: 201 ident: CR6 article-title: Primary resistance to PD-1 blockade mediated by JAK1/2 mutations publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-1223 – volume: 10 start-page: 11428 year: 2020 end-page: 11443 ident: CR10 article-title: BET inhibitor suppresses melanoma progression via the noncanonical NF-kappaB/SPP1 pathway publication-title: Theranostics doi: 10.7150/thno.47432 – volume: 37 start-page: 97 year: 2021 end-page: 111 ident: CR27 article-title: Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma publication-title: Cell Biol. Toxicol. doi: 10.1007/s10565-020-09565-x – volume: 10 start-page: e8446 year: 2018 ident: CR13 article-title: Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma publication-title: Embo. Mol. Med. doi: 10.15252/emmm.201708446 – volume: 24 start-page: 4874 year: 2018 end-page: 4886 ident: CR23 article-title: Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-3697 – volume: 18 start-page: 340 year: 2022 end-page: 356 ident: CR22 article-title: BECN2 (beclin 2) negatively regulates inflammasome sensors through ATG9A-dependent but ATG16L1- and LC3-independent non-canonical autophagy publication-title: Autophagy doi: 10.1080/15548627.2021.1934270 – volume: 12 start-page: eaax2879 year: 2020 ident: CR12 article-title: BET inhibition increases betaIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aax2879 – volume: 79 start-page: 2415 year: 2019 end-page: 2425 ident: CR34 article-title: Inhibition of NF-kappaB-dependent signaling enhances sensitivity and overcomes resistance to BET inhibition in uveal melanoma publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-3177 – volume: 73 start-page: 6264 year: 2013 end-page: 6276 ident: CR8 article-title: BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0122-T – volume: 6 start-page: 219 year: 2016 end-page: 230 ident: CR33 article-title: BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1 publication-title: Theranostics doi: 10.7150/thno.13178 – volume: 8 start-page: 2001596 year: 2021 ident: CR20 article-title: The beneficial role of sunitinib in tumor immune surveillance by regulating tumor PD-L1 publication-title: Adv. Sci. (Weinh.) – volume: 28 start-page: 521 year: 2018 end-page: 526 ident: CR18 article-title: The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma publication-title: Melanoma Res. doi: 10.1097/CMR.0000000000000497 – volume: 9 start-page: eaal1645 year: 2017 ident: CR11 article-title: Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aal1645 – volume: 141 start-page: 2238 year: 2021 end-page: 2249.e2212 ident: CR19 article-title: A combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma publication-title: J. Invest. Dermatol. doi: 10.1016/j.jid.2020.12.038 – volume: 5 start-page: 1183 year: 2016 end-page: 1193 ident: CR16 article-title: BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma publication-title: Cancer Med. doi: 10.1002/cam4.667 – volume: 34 start-page: 537 year: 2019 end-page: 546 ident: CR46 article-title: Downregulated long noncoding RNA GAS5 fails to function as decoy of CEBPB, resulting in increased GDF15 expression and rapid ovarian cancer cell proliferation publication-title: Cancer Biother. Radiopharm. – volume: 98 start-page: 351 year: 2006 end-page: 360 ident: CR43 article-title: The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury publication-title: Circ. Res. doi: 10.1161/01.RES.0000202805.73038.48 – volume: 18 year: 2018 ident: CR28 article-title: Down-regulation of STAT3 induces the apoptosis and G1 cell cycle arrest in esophageal carcinoma ECA109 cells publication-title: Cancer Cell Int. doi: 10.1186/s12935-018-0549-4 – volume: 14 start-page: 6674 year: 2008 end-page: 6682 ident: CR37 article-title: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-5212 – volume: 4 start-page: e04640 year: 2015 ident: CR15 article-title: Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells publication-title: Elife doi: 10.7554/eLife.04640 – volume: 122 start-page: 789 year: 2020 end-page: 800 ident: CR17 article-title: Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma publication-title: Br. J. Cancer doi: 10.1038/s41416-019-0724-y – ident: CR44 – volume: 23 start-page: 1293 year: 2022 ident: CR24 article-title: Cell cycle-dependent transcription: the cyclin dependent kinase Cdk1 is a direct regulator of basal transcription machineries publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms23031293 – volume: 18 start-page: 1457 year: 2012 end-page: 1463 ident: CR36 article-title: Sunitinib therapy for melanoma patients with KIT mutations publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-1987 – volume: 392 start-page: 971 year: 2018 end-page: 984 ident: CR1 article-title: Melanoma publication-title: Lancet doi: 10.1016/S0140-6736(18)31559-9 – volume: 375 start-page: 819 year: 2016 end-page: 829 ident: CR7 article-title: Mutations associated with acquired resistance to PD-1 blockade in melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1604958 – volume: 165 start-page: 58 year: 2022 end-page: 70 ident: CR31 article-title: Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2022.01.004 – volume: 19 start-page: 598 year: 2013 end-page: 609 ident: CR30 article-title: The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-2731 – volume: 29 start-page: 237 year: 2008 end-page: 243 ident: CR25 article-title: CDC6: from DNA replication to cell cycle checkpoints and oncogenesis publication-title: Carcinogenesis doi: 10.1093/carcin/bgm268 – volume: 7 start-page: 1248 year: 2017 end-page: 1265 ident: CR4 article-title: Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-0401 – volume: 14 start-page: 75 year: 2022 end-page: 89 ident: CR32 article-title: Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers publication-title: World J. Gastrointest. Oncol. doi: 10.4251/wjgo.v14.i1.75 – volume: 31 start-page: 363 year: 2020 ident: 936_CR42 publication-title: Cell Metab. doi: 10.1016/j.cmet.2019.12.005 – volume: 122 start-page: 789 year: 2020 ident: 936_CR17 publication-title: Br. J. Cancer doi: 10.1038/s41416-019-0724-y – volume: 24 start-page: 4874 year: 2018 ident: 936_CR23 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-3697 – volume: 29 start-page: 237 year: 2008 ident: 936_CR25 publication-title: Carcinogenesis doi: 10.1093/carcin/bgm268 – volume: 69 start-page: 2506 year: 2009 ident: 936_CR48 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-4323 – volume: 73 start-page: 6264 year: 2013 ident: 936_CR8 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0122-T – volume: 37 start-page: 97 year: 2021 ident: 936_CR27 publication-title: Cell Biol. Toxicol. doi: 10.1007/s10565-020-09565-x – volume: 18 start-page: 1457 year: 2012 ident: 936_CR36 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-1987 – volume: 9 start-page: 1547 year: 2021 ident: 936_CR45 publication-title: Ann. Transl. Med. doi: 10.21037/atm-21-4764 – volume: 21 start-page: 3230 year: 2015 ident: 936_CR29 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2701 – volume: 15 start-page: 2148 year: 2009 ident: 936_CR38 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-1332 – volume: 36 start-page: 498 year: 2019 ident: 936_CR26 publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.10.002 – volume: 165 start-page: 58 year: 2022 ident: 936_CR31 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2022.01.004 – volume: 14 start-page: 6674 year: 2008 ident: 936_CR37 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-5212 – volume: 17 start-page: 2417 year: 2011 ident: 936_CR40 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-10-2402 – volume: 10 start-page: 11428 year: 2020 ident: 936_CR10 publication-title: Theranostics doi: 10.7150/thno.47432 – volume: 28 start-page: 521 year: 2018 ident: 936_CR18 publication-title: Melanoma Res. doi: 10.1097/CMR.0000000000000497 – volume: 98 start-page: 351 year: 2006 ident: 936_CR43 publication-title: Circ. Res. doi: 10.1161/01.RES.0000202805.73038.48 – volume: 7 start-page: 78 year: 2021 ident: 936_CR49 publication-title: Cell Death Discov. doi: 10.1038/s41420-021-00462-8 – volume: 8 start-page: 2001596 year: 2021 ident: 936_CR20 publication-title: Adv. Sci. (Weinh.) – volume: 11 start-page: e9081 year: 2019 ident: 936_CR35 publication-title: Embo. Mol. Med. doi: 10.15252/emmm.201809081 – volume: 18 start-page: 340 year: 2022 ident: 936_CR22 publication-title: Autophagy doi: 10.1080/15548627.2021.1934270 – volume: 4 start-page: e04640 year: 2015 ident: 936_CR15 publication-title: Elife doi: 10.7554/eLife.04640 – volume: 18 year: 2018 ident: 936_CR28 publication-title: Cancer Cell Int. doi: 10.1186/s12935-018-0549-4 – volume: 19 start-page: 598 year: 2013 ident: 936_CR30 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-2731 – volume: 12 start-page: eaax2879 year: 2020 ident: 936_CR12 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aax2879 – volume: 12 year: 2022 ident: 936_CR2 publication-title: Clin. Transl. Med. doi: 10.1002/ctm2.722 – volume: 384 start-page: 2229 year: 2021 ident: 936_CR5 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra2034861 – volume: 5 start-page: 1183 year: 2016 ident: 936_CR16 publication-title: Cancer Med. doi: 10.1002/cam4.667 – volume: 23 start-page: 1293 year: 2022 ident: 936_CR24 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms23031293 – volume: 7 start-page: 1248 year: 2017 ident: 936_CR4 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-0401 – volume: 9 start-page: 802 year: 2018 ident: 936_CR21 publication-title: Oncotarget doi: 10.18632/oncotarget.22696 – volume: 17 start-page: 592 year: 2021 ident: 936_CR39 publication-title: Nat. Rev. Endocrinol. doi: 10.1038/s41574-021-00529-7 – volume: 7 start-page: 188 year: 2017 ident: 936_CR6 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-1223 – volume: 79 start-page: 2415 year: 2019 ident: 936_CR34 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-3177 – volume: 392 start-page: 971 year: 2018 ident: 936_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(18)31559-9 – volume: 141 start-page: 2238 year: 2021 ident: 936_CR19 publication-title: J. Invest. Dermatol. doi: 10.1016/j.jid.2020.12.038 – volume: 32 start-page: 1 year: 2022 ident: 936_CR47 publication-title: Melanoma Res. doi: 10.1097/CMR.0000000000000790 – volume: 13 start-page: 905 year: 2017 ident: 936_CR14 publication-title: Mol. Syst. Biol. doi: 10.15252/msb.20166796 – volume: 14 start-page: 75 year: 2022 ident: 936_CR32 publication-title: World J. Gastrointest. Oncol. doi: 10.4251/wjgo.v14.i1.75 – volume: 9 start-page: 268 year: 2019 ident: 936_CR3 publication-title: Front. Oncol. doi: 10.3389/fonc.2019.00268 – volume: 136 start-page: 2444 year: 2016 ident: 936_CR41 publication-title: J. Invest. Dermatol. doi: 10.1016/j.jid.2016.07.016 – ident: 936_CR44 doi: 10.1007/s13258-022-01328-8 – volume: 9 start-page: eaal1645 year: 2017 ident: 936_CR11 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aal1645 – volume: 375 start-page: 819 year: 2016 ident: 936_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1604958 – volume: 11 year: 2020 ident: 936_CR9 publication-title: Nat. Commun. doi: 10.1038/s41467-020-15290-0 – volume: 6 start-page: 219 year: 2016 ident: 936_CR33 publication-title: Theranostics doi: 10.7150/thno.13178 – volume: 34 start-page: 537 year: 2019 ident: 936_CR46 publication-title: Cancer Biother. Radiopharm. – volume: 10 start-page: e8446 year: 2018 ident: 936_CR13 publication-title: Embo. Mol. Med. doi: 10.15252/emmm.201708446 |
| SSID | ssj0025474 |
| Score | 2.4284177 |
| Snippet | Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better... Cancer: a drug combination for combating melanoma Drugs that target proteins involved in issuing stop and start commands to cancer-related genes help to... |
| SourceID | nrf doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 364 |
| SubjectTerms | 13/109 13/2 13/31 13/51 13/95 14/1 38/47 38/91 631/67/1813/1634 64 64/60 692/308/575 82 82/80 Antitumor activity Antitumor agents Apoptosis Biomedical and Life Sciences Biomedicine Cancer Cancer therapies Cell cycle Cell Cycle Proteins Cell death Cell Line, Tumor Cell Proliferation FDA approval Growth Differentiation Factor 15 - genetics Growth Differentiation Factor 15 - pharmacology Humans Inhibitor drugs Kinases Medical Biochemistry Melanoma Melanoma - drug therapy Molecular Medicine Nuclear Proteins - metabolism Proteins Stat3 protein Stem Cells Sunitinib - pharmacology Synergism Targeted cancer therapy Transcription Factors - metabolism Xenograft Model Antitumor Assays Xenografts 생화학 |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3LbtQw0EI9IC4IWh6BgoxAXCDqJn4kObbQUpCWUyv1ZvlJo3a91T4Oy9cz43gXlueFU6R4LDnzyMx4XoS8sj64tmG-9IzLkjOusVjZlNxo70ZM12aE9c7jz_L0nH-6EBc_jPrCnLChPfCAuANpO-2YFGFkPHfCaQkWMXO6YsI7rz3-fUHnrZ2p7GoJ3vBcIjNi7cG8qusGk21ZiS68LFdbaih16wflEmfhd4bmr_mSPwVNky46uUfuZiOSHg6Hv09u-bhL9g4jONCTFX1NU1pnui_fJbfHOXq-R8ZHx2e0j5e96XHGDp2vsPCv_-op3sbS-RITiWJvAIZO_LWO04mmeZAP_fD-pBIAc5MzZ-MDcn5yfPbutMzjFEoLNtmidK4F40tY43jXtg4swSC5EJYDTVDzu8pZ510nUOhlqA0W7UpAduCtrQJjD8lOnEb_mNDggpXW81ABiZnv2qbrkCJOGy1dIwpSrbGrbO41jiMvrlWKebNWDRRRQBGVKKJWBXmz2XMzdNr4K_QREm0DiV2y0wvgHZV5R_2LdwryEkiurmyf9uPzy1RdzRT4Eh8x-a1rwNotyP6aJVQW8LmqsVUYeJcMll9slkE0Md6io58uEQacUSZZ3Rbk0cBBm_My2SDbwkqzxVtbH7S9EvvL1P4bHOSqkbwgb9dc-P1Yf0bYk_-BsKfkTp2ECNN59snOYrb0z8AoW5jnSf6-AakuM9w priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSIgXBBsfgYGMQLxAtCb-SPKENlgZSOVpk_pmObazRVud0rQP5a_nznVblY89RYovkuO7s3_n-yLknXGNLQvmUse4TDnjGpOV65TX2tkB03k9wHzn0Q95dsG_j8U4Xrj1MaxyvSeGjdp2Bu_Ij3KszQRwnslP058pdo1C72psoXGX3MPSZSjVxXhrcAkeqjBnADFSBudWTJoZsPKoh5cFht-yFI16mS53DqZQvx-OGz9r_gU9_46g_MONGk6n4SPyMMJKerySg8fkjvP75ODYg0k9WdL3NAR6hhv0fXJ_FP3pB2R0cnpOW3_V1i123aH9ElMB21-O4v0s7RcYWuTbGmjoxN1o3000ja196Ncvw0wAzTTG0von5GJ4ev75LI0NFlIDKG2eWlsCHBOmtrwqSwvYsJFcCMOBS4gFbGaNdbYSuA3IJq8xjVeWOWt4abKGsadkz3fePSe0sY2RxvEmA6YzV5VFVemMCatrLW0hEpKtV1eZWH0cm2DcqOAFZ6VacUQBR1TgiFom5MPmm-mq9sat1CfItA0l1s0OL7rZpYpqqKSptGVSNIPacQuzk2BfMYszddZpl5C3wHJ1bdrwPT4vO3U9U2BdfMNwuKoA_JuQw7VIqKjyvdoKaELebIZBWdEDo73rFkgD5imTLC8T8mwlQZv5MlnkAN5gpNiRrZ0f2h3x7VUoCA4mc1ZInpCPayncTuv_C_bi9r94SR7kQT0wdOeQ7M1nC_cKANi8fh207Dfjtyuy priority: 102 providerName: ProQuest |
| Title | BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression |
| URI | https://link.springer.com/article/10.1038/s12276-023-00936-y https://www.ncbi.nlm.nih.gov/pubmed/36720918 https://www.proquest.com/docview/2781414936 https://www.proquest.com/docview/2771636328 https://pubmed.ncbi.nlm.nih.gov/PMC9981764 https://doaj.org/article/6c9ad365f0be4d5da61823da135edeae https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002937530 |
| Volume | 55 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Experimental and Molecular Medicine, 2023, 55(0), , pp.364-376 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELf2ISFeEGzAAqMyAvECEU3s2MljW1pGpU4INqlvlmM7W7Q1mfrxUP567tykqDCQeIpkn6Wz7y6-s393JuStcYVNJXOhY1yEnHGNycp5yHPtbJfpOO9ivvPkXJxd8vE0me6RuM2F8aB9X9LS_6ZbdNjHRRTHEuGyLMQgXITrfXKIpdpBtw97vfH38TbMSrjkTXpMl6X3jNzZgnylfthYqnlxn5P5J1bytwtTvw-NHpNHjQNJexuWn5A9Vx2R4x7Mpp6t6TvqIZ3-rPyIPJg0N-fHZNIfXtCyui7zEt_XoYs1Jv2VPxzFk1i6WCGIqCpzoKEzd6ureqZp84gP_fxpFCVAc9egZqun5HI0vBichc1TCqEBf2wZWpuC45WY3PIsTS14gYXgSWI4yAN3fRtZY53NEjR4UcQ5JuyKNGYFT01UMPaMHFR15U4ILWxhhHG8iEC8zGWpzDIdscTqXAsrk4BE7eoq09QZx-cubpW_72ap2khEgUSUl4haB-T9dszdpsrGP6n7KLQtJVbI9g31_Eo1GqOEybRlIim6ueMWuBMQSTGLnDrrtAvIGxC5ujGlH4_fq1rdzBXEEV8Q-JZJ8HQDctqqhGqMe6FiLBMGkSWD7tfbbjBLvGvRlatXSAOBKBMsTgPyfKNBW36ZkDG4adAjd3RrZ0K7PVV57Ut_Q3AcScED8qHVwl9s_X3BXvwf-UvyMPbmgqCdU3KwnK_cK3C9lnmH7Mup7DQWB9_-8PzrN2gdiEHHH2f8BBtxLco |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIQEvaGxcwgYYcXmBaE3sOMkDQhtbadm6p07qm3FsZ4u2JqUXofKj-I2c4yatymVve4oUO5Ljc-zznTshb7TNTRIz61vGhc8ZV5isnPk8U9a0mAqzFuY7985E55x_HUSDDfKryYXBsMrmTnQXtak02sj3Q6zNBHCeiU-j7z52jULvatNCY8EWJ3b-A1S2ycfuEdD3bRi2j_ufO37dVcDXAE2mvjEJYJBIZ4anSWIAEOWCR5HmsDQUgCYw2liTRsj7Ig8zzF0VSchynuggRwMoXPl3QPC2UNmLBysFL-Ku6nMAkMZnICfrJJ0WS_Yn8DLGcF_moxFB-PM1Qej6BYB4K8f5v6Du3xGbf7htnTRsb5EHNYylBwu-e0g2bLlNdg5KUOGHc_qOusBSZ7HfJnd7tf9-h_QOj_u0KC-LrMAuP3Qyx9TD4qelaA-mkxmGMpVFBnPo0F6rshoqWrcSol-O2kEEc0Z17G75iJzfytY_JptlVdqnhOYm10JbngfAZMymSZymKmCRUZkSJo48EjS7K3Vd7RybblxL53VniVxQRAJFpKOInHvk_fKb0aLWx42zD5Foy5lYp9u9qMYXsj72UuhUGSaivJVZbmB1AvQ5ZnCl1lhlPfIaSC6vdOG-x-dFJa_GErSZLobfpTHgbY_sNSwh6ytmIlcHwiOvlsNwOaDHR5W2muEcUIeZYGHikScLDlqul4k4BLAII_Eab6390PpIWVy6AuSgogex4B750HDhaln_37BnN__FS3Kv0--dytPu2ckuuR-6o4JhQ3tkczqe2ecA_qbZC3fiKPl220f8N1BIZus |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1Jo6aeIFwcYlMMATlxeI2sSOkzwgtK4tK6PVhDZpb15iO1u0NSm9CJVP4-s4x006lcve9hQpdqQTn_vxuRDyRplMRyEzrmFcuJzxBIuVU5enidEtlvhpC-udB0NxeMq_nAVnG-RXXQuDaZW1TLSCWpcKY-RNH3szgTnPRDOr0iKOO71P4-8uTpDCm9Z6nMaSRI7M4ge4b9OP_Q7g-q3v97onB4duNWHAVWCmzFytI7BHApVqHkeRBuMoEzwIFAcwURlqTyttdBwgH4jMT7GOVUQ-y3ikvAyDoSD-N0P0ihpks90dHn9buXsBtz2gPTBwXAZasyrZabGoOYWXISb_MhdDCsJdrKlFOz0AlF0xyf5l-P6dv_nHJa7Vjb0H5H5l1NL9JRU-JBum2CY7-wU49KMFfUdtmqmN32-TrUF1m79DBu3uCc2LyzzNceYPnS6wEDH_aShGh-l0jolNRZ7CHjoy10lRjhJaDRainzs9L4A94yqTt3hETu_k8B-TRlEW5imhmc6UUIZnHpAcM3EUxnHisUAnaSJ0GDjEq09Xqqr3OY7guJb2Dp5FcokRCRiRFiNy4ZD3q2_Gy84ft-5uI9JWO7Frt31RTi5kJQSkUHGimQiyVmq4BugEeHdMI6RGm8Q45DWgXF6p3H6Pz4tSXk0k-DZ9TMaLQ7C-HbJbk4SsBM5U3rCHQ_ZWyyAq8P4nKUw5xz3gHDPB_MghT5YUtIKXidAH0xFWwjXaWvuh9ZUiv7TtyMFh90LBHfKhpsIbsP5_YM9u_4tXZAvYW37tD4-ek3u-5RTMIdoljdlkbl6AJThLX1YsR8n5XXP5b4q_bIY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=BET+inhibitors+synergize+with+sunitinib+in+melanoma+through+GDF15+suppression&rft.jtitle=Experimental+%26+molecular+medicine&rft.au=Zeng%2C+Furong&rft.au=Li%2C+Yayun&rft.au=Meng%2C+Yu&rft.au=Sun%2C+Huiyan&rft.date=2023-02-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=1226-3613&rft.eissn=2092-6413&rft.volume=55&rft.issue=2&rft.spage=364&rft.epage=376&rft_id=info:doi/10.1038%2Fs12276-023-00936-y&rft_id=info%3Apmid%2F36720918&rft.externalDocID=PMC9981764 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2092-6413&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2092-6413&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2092-6413&client=summon |